Connect with us

Micro Cap Insider

Major Comeback on (INND) InnerScope Hearing Tech; Maker of FDA-Registered Direct-to-Consumer Self-Fitting-Self-Adjusting Hearing Aids

Published

on

(INND) InnerScope Hearing Technologies recently made a spectacular move up the charts over the past few months from triple zeroes to highs of $0.098 per share. Since than INND has dipped significantly however now looks way oversold and has a significant gap to fill from current levels. INNID also has massive liquidity as legions of new shareholders accumulate. INND has emerged as a volume powerhouse trading 638 million shares or about $15 million in dollar volume on Friday alone. The stock started moving up in January as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than INND has.     

Its easy to get excited about INND, a manufacturer, distributor, and retailer of FDA-Registered Direct-to-Consumer Self-Fitting-Self-Adjusting Hearing Aids. Last week INND reported it plans to launch its latest breakthroughs in Hearing Technology with its New Smartphone Controlled Direct-to-Consumer Self-Fitting-Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. With the launch planned to begin spring of 2021, InnerScope as a wholesale vendor for Walmart will be updating its storefront on Walmart.com and other major online retailers for more enhanced visibility to achieve greater sales conversions. Concurrently, InnerScope is working on rolling out its Self-Fitting Hearing Aids and its other Hearing Products with major brick and mortar retailers starting Spring 2021. InnerScope is also currently in the middle of completely revamping its NoHassleHearing.com eCommerce sales platform. InnerScope has brought in award-winning Shopify SEO experts to develop advanced SEO features with Shopify themes with fully optimized product filter/tag pages, which unleash 1000’s more store URLs in the search engines. InnerScope expects this will increase NoHassleHearing.com’s organic visibility by 1000% in just four weeks. 

(INND) InnerScope Hearing Technologies is a manufacturer, distributor, and retailer of FDA-Registered Direct-to-Consumer Self-Fitting-Self-Adjusting Hearing Aids, Self-Fitting-Self-Adjusting Personal Sound Amplifiers Products, Doctor-Formulated Dietary Hearing & Tinnitus Supplements, and Assorted Ear & Hearing Health-Related Products. its mission is to improve the quality of life of the 70 million people in North America who suffer from hearing impairment and hearing-related issues. The management team of InnerScope is applying decades of industry experience and believes it’s well-positioned to directly benefit from the Over the Counter Hearing Aid Act (expected to be enacted in Spring/Summer 2021) with its Affordable Self-Fitting – Self-Adjusting Hearing Technology combined with an innovative point of sale Hearing Screening Kiosks which is designed for consumers with mild-to-moderate hearing loss to have access to purchase Over The Counter hearing aids without being seen by a hearing care professional.  

On Feburary 17 INND announced its plans to launch its latest breakthroughs in Hearing Technology with its New Smartphone Controlled Direct-to-Consumer (“DTC”) Self-Fitting-Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service (“Self-Fitting Hearing Aids”). With the launch of Self-Fitting Hearing Aids, InnerScope will be replacing all of its legacy hearing aid products that are either not rechargeable or requires separate remote control to make adjustments. The Self-Fitting Hearing Aids provides the consumers an easy, accurate, and straightforward way to fit themselves in under 5 minutes using their Smartphone. Moreover, InnerScope believes its Self-Fitting Hearing Aids deliver the same quality hearing experience and satisfaction for thousands of dollars less than a professionally in-office fitted hearing aid. 

With the launch planned to begin spring of 2021, InnerScope as a wholesale vendor for Walmart will be updating its storefront on Walmart.com and other major online retailers for more enhanced visibility to achieve greater sales conversions. Concurrently, InnerScope is working on rolling out its Self-Fitting Hearing Aids and its other Hearing Products with major brick and mortar retailers starting Spring 2021. InnerScope is currently working with additional upcoming retailers on offering InnerScope Hearing Products once the final guidance for the Over-the-Counter Hearing Aid Act is announced by the FDA (expected Spring/Summer 2021). 

INND operates in the booming hearing aids space;  According to a report from Fortune Business Insights the global hearing aids market is set to gain impetus from the increasing adoption of telehealth among audiologists to prevent patient traffic. The report further states that the market size was USD 8.99 billion in 2019 and is projected to reach USD 13.38 billion by 2027, exhibiting a CAGR of 8.2% during the forecast period.

Investor Sentiment in INND is high:

To Find out the inside Scoop on INDD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

INND

InnerScope is also currently in the middle of completely revamping its NoHassleHearing.com eCommerce sales platform. InnerScope has brought in award-winning Shopify SEO experts to develop advanced SEO features with Shopify themes with fully optimized product filter/tag pages, which unleash 1000’s more store URLs in the search engines. InnerScope expects this will increase NoHassleHearing.com’s organic visibility by 1000% in just four weeks. 

InnerScope’s Self-Fitting Hearing Aids are: AFFORDABLE, saving thousands of dollars without sacrificing hearing quality. InnerScope’s Self-Fitting Hearing Aids delivers the same overall hearing experience and satisfaction compared to professionally in-office fitted hearing aids with similar quality and features. FULLY RECHARGEABLE includes a compact charger that lasts up to 20 hours with 1.5 hours charge. (No need to change or buy conventional hearing aid batteries). EASY & CONVENIENT with no assistance needed or required. No need to make costly and unnecessary trips to a hearing care professional to be fitted or have any adjustments. InnerScope’s self-fitting Hearing Aids are instantly fit using a Smartphone, Apple iPad, or Android Tablet. The Smartphone and Smart Device are also used to make instant fine-tuning adjustments on the fly using the Self-Adjusting features. SIMPLE & ACCURATE with the unique built-in Self-Testing and Self-Fitting programming feature allows the most current and accurate Hearing Profile programmed into the hearing aid at all times. The Self-Testing and Self-Fitting feature conduct a calibrated pure-tone air conduction hearing test for each ear (the same type of hearing test performed by a hearing care professional) at any time to ensure maximum hearing benefit with the hearing aids. 

InnerScope’s self-fitting Hearing Aid also has a built-in Professional Remote Programming & Support feature, allowing one of InnerScope’s licensed hearing care professionals to assist (if needed) to maximize the hearing aid performance through automatically adjusting and fine-tuning the hearing aids remotely. 

Matthew Moore, CEO of InnerScope Hearing Technologies, commented, “InnerScope is excited to launch its Self-Fitting Hearing Aids with its B2C and B2B Wholesale Retail Partners. InnerScope is planning a launch of an Omni-Channel marketing strategy to significantly increase its B2C sales, including national infomercials, TV/Radio commercials, and other online/digital marketing forms. As a B2B Wholesaler to some of the world’s largest retailers, InnerScope will be working with the retailers to create a General Hearing Health and Hearing Products Awareness campaign for their customers. These campaigns will drive awareness of the extreme health consequences of a person living with untreated hearing loss and market InnerScope’s Hearing Products to help the hearing-impaired community through the retailer. All InnerScope’s Current and upcoming Retailers are excited to add InnerScope’s Direct-to-Consumer Self-Fitting Hearing Aids and other related Hearing Products to their customers. InnerScope expects its initial sizeable inventory of the NEW Direct-to-Consumer Hearing Aids within the next few weeks and will instantly start selling the products. According to the World Health Organization (WHO), disabling hearing loss is projected to affect 630 million people worldwide by 2030, with less than 15% currently using hearing assistance. Therefore, InnerScope is prepared to help thousands if not millions of people around the world in a burgeoning hearing-impaired market.” 

For More on INDD Subscribe Right Now!

INND recently made a spectacular move up the charts over the past few months from triple zeroes to highs of $0.098 per share. Since than INND has dipped significantly however now looks way oversold and has a significant gap to fill from current levels. INNID also has massive liquidity as legions of new shareholders accumulate. INND has emerged as a volume powerhouse trading 638 million shares or about $15 million in dollar volume on Friday alone. The stock started moving up in January as a new era of penny stock speculators fueled by robinhood and its 100 million new trading accounts take on the bulletin boards. These are different times than just a few short years ago; now penny stocks such as TSNP can achieve a $6 billion plus market valuation and trade $375 million in dollar volume in a day on the bulletin boards. And TSNP has no stronger fundamentals than INND has.      Its easy to get excited about INND, a manufacturer, distributor, and retailer of FDA-Registered Direct-to-Consumer Self-Fitting-Self-Adjusting Hearing Aids. Last week INND reported it plans to launch its latest breakthroughs in Hearing Technology with its New Smartphone Controlled Direct-to-Consumer Self-Fitting-Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. With the launch planned to begin spring of 2021, InnerScope as a wholesale vendor for Walmart will be updating its storefront on Walmart.com and other major online retailers for more enhanced visibility to achieve greater sales conversions. Concurrently, InnerScope is working on rolling out its Self-Fitting Hearing Aids and its other Hearing Products with major brick and mortar retailers starting Spring 2021. InnerScope is also currently in the middle of completely revamping its NoHassleHearing.com eCommerce sales platform. InnerScope has brought in award-winning Shopify SEO experts to develop advanced SEO features with Shopify themes with fully optimized product filter/tag pages, which unleash 1000’s more store URLs in the search engines. InnerScope expects this will increase NoHassleHearing.com’s organic visibility by 1000% in just four weeks. INND operates in the booming hearing aids space;  According to a report from Fortune Business Insights the global hearing aids market  size was USD 8.99 billion in 2019 and is projected to reach USD 13.38 billion by 2027, exhibiting a CAGR of 8.2% during the forecast period. We will be updating on INND when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with INND.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in INND either long or short and we have not been compensated for this article

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions

Published

on

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development.

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.

Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.

To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.

Hostile takeover?

While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.

The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54%  prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.

Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.

We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells

Published

on

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601.

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year. 

“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.

Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:

To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.

While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.

These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.

However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.

These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”

MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.

About Marker Therapeutics, Inc.

Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.

Capital structure

Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.

It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.

We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PDPics from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.